Demonstrated in pivotal clinical studies.
Demonstrated in pivotal clinical studies, after six months, 96 % of patients who received a single dose of Aclasta a therapeutic response, compared with 74 % of patients who received 30 mg of risedronate has, for 60 days.1 after more than 12 months the vast majority of patients, the therapeutic response to Reclast. Get After six months After six months phosphatase in serum – a key marker for bone turnover – 89 % of 89 % of Aclasta -treated patients compared with 58 % of the risedronate patients.1.
Paget’s disease, the second most common metabolic bone disease after osteoporosis6 can lead to serious consequences if not appropriate. It dealt with a chronic skeletal disorder is in many patients causing pain, fractures and deformities seriously impede seriously hamper their ability to perform routine activities of daily living.7 This is a disease that can be difficult to diagnose, because not all patients will experience a significant symptoms7 so many untreated.Q. How deformities the brain chemical cause depression?
Answer: Well, there is evidence from both animal studies and those to humans that the from depression from depression, anomalies of in the nerve transmission both in in both the serotonin and noradrenalin systems.